PHASE I TRIAL OF SUBCUTANEOUS CALCITRIOL AND PREDNISONE IN TUMORS

皮下骨化三醇和泼尼松治疗肿瘤的 I 期试验

• 批准号: 5218441
• 负责人: DAVID SMITH
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5218441
• 关键词: 1,25 dihydroxycholecalciferol; clinical research; clinical trial phase I; combination chemotherapy; drug screening /evaluation; hormone therapy; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; prednisone

Vitamin D is a steroid hormone best known for its activity in regulating calcium and bone metabolism. The active form of vitamin D is calcitriol [1,25-(OH)2D3]. Epidemiologic evidence suggests that calcitriol may play an important role in the development of colon and prostate cancer. Preclinical study of cancer cell lines have shown that calcitrol can kill tumor cells, however, animal studies have shown that the doses required also induce hypercalcemia. Prednisone is effective in reducing hypercalcemia. The premise of this study is to conduct a phase I;II study to evaluate the combined approach of calcitrol and prednisone in patients with advanced cancer.

维生素D是一种类固醇激素，以其调节 钙和骨代谢。 维生素D的活性形式是骨化三醇 [1，25-（OH）2D3]。 流行病学证据表明，骨化三醇可能发挥 在结肠癌和前列腺癌的发展中起重要作用。 癌细胞系的临床前研究表明，骨化三醇可以杀死 然而，动物研究表明， 也会引起高钙血症。 强的松能有效降低 高钙血症 这项研究的前提是进行第一阶段; 评价骨化三醇和泼尼松联合应用治疗原发性肝癌的研究 晚期癌症患者。